The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass

European Journal of Cardio-thoracic Surgery

Volumn 35, Issue 6, 2009, Pages 988-994

  Adluri, Rajeshwara Krishna Prasad ^a   Singh, Arvind V ^a   Skoyles, Julian ^a   Robins, Adrian ^a   Hitch, Anthony ^a   Baker, Mya ^a   Mitchell, Ian Moore ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Cardiopulmonary bypass; Gut ischaemia; Liver function; Splanchnic perfusion

Indexed keywords

DOPEXAMINE; FENOLDOPAM; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG MECHANISM; HEART RATE; HUMAN; HYPOTHERMIC CARDIOPULMONARY BYPASS; LIVER BLOOD FLOW; LIVER FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DOPAMINE; DOUBLE-BLIND METHOD; FEMALE; FENOLDOPAM; HEMODYNAMICS; HUMANS; HYPOTHERMIA, INDUCED; LIVER; LIVER CIRCULATION; MALE; MIDDLE AGED; MONITORING, INTRAOPERATIVE; PERIOPERATIVE CARE; PROSPECTIVE STUDIES; VASODILATOR AGENTS;

EID: 67349274989     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.01.024     Document Type: Article

References (24)

1. Ohri S.K., and Velissaris T. Gastrointestinal dysfunction following cardiac surgery. Perfusion 21 (2006) 215-223
2. Paparella D., Yau T.M., and Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 21 (2002) 232-244
3. Tsunooka N., Maeyama K., Hamada Y., Imagawa H., Takano S., Watanabe Y., and Kawachi K. Bacterial translocation secondary to small intestinal mucosal ischemia during cardiopulmonary bypass. Measurement by diamine oxidase and peptidoglycan. Eur J Cardiothorac Surg 25 (2004) 275-280
4. Jansen N.J.G., van Overen W., Gu Y.J., van Vilet M.H., Eijsman L., and Wildevuur C.R.H. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54 (1992) 744-748
5. Riddington D.W., Venkatesh B., Boivin C.M., Bonser R.S., Elliott T.S.J., Marshall T., Muntford P.J., and Bion J.F. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 275 (1996) 1007-1012
6. Singer I., and Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. American journal of kidney diseases 31 5 (1998) 743-755
7. Karzai W., Gunnicker M., Scharbert G., Vorgrimler-Karzai U.M., and Priebe H.J. Effects of dopamine on oxygen consumption and gastric mucosal blood flow during cardiopulmonary bypass in humans. Br J Anaesth 77 (1996) 603-606
8. Parvianen I., Ruokonen E., and Takala J. Dobutamine induced disassociation between changes in splanchnic blood flow and gastric intramucosal pH after cardiac surgery. Br J Anaesth 74 (1995) 277-282
9. McNichol L., Anderson L.W., Liu G., Doolan L., and Baek L. Markers of splanchnic perfusion and intestinal translocation of endotoxins during cardiopulmonary bypass: effects of dopamine and Milrinone. J Cardiothorac Vasc Anesth 13 3 (1999) 292-298
10. Bach F., Grundmann U., Bauer M., Buchinger H., Soltesz S., Graeter T., Larsen R., and Silomon M. Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol Scand 46 (2002) 1227-1235
11. Sharpe D.A.C., Mitchel I.M., Kay E.A., Mc Goldrick J.P., Munsch C.M., and Kay P.H. Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine. Perfusion 14 (1999) 29-36
12. Halpenny M., Lakshmi S., O'Donnell A., O'Callaghan-Enright S., and Shorten G.D. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 56 (2001) 953-960
13. Bove T., Landoni G., Calabro M.G., Aletti G., Marino G., Cerchierini E., Crescenzi G., and Zangrillo A. Renoprotective action of fenoldopam in high risk patients undergoing cardiac surgery. A prospective, double blinded randomised clinical trial. Circulation 111 (2005) 3230-3235
14. Mathur V.S., Swan S.K., Lambrecht L.J., Anjum S., Fellmann J., McGuire D., Epstein M., and Luther R.R. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 27 9 (1999) 1832-1837
15. Ranucci M., Soro G., Barzaghi N., Locatelli A., Giordano G., Vavassori A., Manzato A., Melchiorri C., Bove T., Juliano G., and Uslenghi M.F. Fenoldopam prophylaxis of post operative acute renal failure in high risk cardiac surgery. Ann Thorac Surg 78 (2004) 1332-1338
16. Mitchel I.M., Pollock J.C.S., and Jamieson M.P.G. The validation of auricular densitometry for indocyanine green clearance measurement of blood flow during and after cardiopulmonary bypass in children. Perfusion 10 (1995) 197-208
17. Okano N., Miyoshi S., Owada R., Fujita N., Kadoi Y., Saito S., Goto F., and Morita T. Impairment of hepatosplanchnic oxygenation and increase of serum hyaluronate during normothermic and mild hypothermic cardiopulmonary bypass. Anaesth Analg 95 2 (2002) 278-286
18. Braun J.P., Schroeder T., Buehner S., Dohmen P., Moshirzadeh M., Grosse J., Strett F., Schlaefke A., Armstrong V.W., Oellerich M., Lochs H., Konertz W., Kox W.J., and Spies C. Splanchnic oxygen transport, hepatic function and gastrointestinal barrier after normothermic cardiopulmonary bypass. Acta Anaesthesiol Scan 48 (2004) 697-703
19. Ascione R., Talpahewa S., Rajakaruna C., Reeves B.C., Lovell T., Cohen A., and Angelini G.D. Splanchnic organ injury during coronary surgery with or without cardiopulmonary bypass: a randomised controlled trial. Ann Thorac Surg 81 (2006) 97-103
20. Wang M.J., Chao A., Huang C.H., Tsai C.H., Lin F.Y., Wang S.S., Liu C.C., and Chu S.H. Hyperbilirubinemia after cardiac operation. Incidence, risk factors, and clinical significance. J Thorac Cardiovasc Surg 108 (1994) 429-436
21. Kumle B., Boldt J., Suttner S.W., Piper S.N., Lehmann A., and Blome M. Influence of prolonged cardiopulmonary bypass times on splanchnic perfusion and markers of splanchnic organ function. Ann Thorac Surg 75 (2003) 1558-1564
22. Halpenny M., Lakshmi S., O'Donnell A., O'Callaghan-Enright, and Shorten G. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 56 (2001) 953-960
23. Caimmi P., Pagani L., Micalizzi E., Fiume C., Guani S., Bernardi M., Parodi F., Cordero G., Fregonara M., Kapetanakis E., Panella M., and Gasperis C.D. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth 4 (2003) 491-494
24. Garwood D., Swamidoss C.P., Davis E.A., Samson L., and Hines R.L. A case series of low dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction. J Cardiothorac Vasc Anesth 17 (2003) 17-21